Drug Stops 90% of Pancreatic Cancer Migration in Lab Tests
Reported byScienceAlert ↗·Sourced by Goodlede
A team from Florida A&M University College of Pharmacy and Pharmaceutical Sciences tested polyisoprenylated cysteinyl amide inhibitors (PCAIs) on pancreatic cancer cells with KRAS mutations. The compound NSL-YHJ-2-27 blocked more than 90 percent of cancer cell migration at low concentrations and triggered programmed cell death in 3D tumor models, offering a potential targeted therapy for KRAS-driven pancreatic cancers previously considered 'undruggable.'
Results are from lab-grown cell models and miniature 3D tumors; human clinical trials would be required to determine safety and efficacy in patients.
Goodlede runs a two-pass source check on every story: one pass finds it, a second skeptical pass re-verifies the claim and writes what it doesn’t prove. This is a source check, not an independent fact-check — confirm anything important at the link above.
Read the full story at ScienceAlert
Read original story ↗More good news, verified daily.
Goodlede covers positive developments across science, nature, rights, and human achievement — verified before they appear. No hype, no roundups, no PR wires.
© 2026 Wag Media, LLC
More from Goodlede
Environment
Crackdown lets rainforest reclaim illegal road in rare win for the Amazon
Mongabay · Verified
Animals
First cinereous vulture chicks hatch in the Bulgarian Rhodopes in over 30 years
Rewilding Europe · Verified
Environment
Targeted conservation in Brazil could help protect the Amazon's flying rivers
Mongabay · Caution